Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with Rituximab.
Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with Rituximab.
复制标题
DOI：
10.1016/j.nmd.2023.02.005
复制
发表时间：
2023-03
影响因子：
2.8
通讯作者：
Evoli, Amelia
中科院分区：
文献类型：
--
作者：
Damato, Valentina;Spagni, Gregorio;Monte, Gabriele;Scandiffio, Letizia;Cavalcante, Paola;Zampetti, Nicole;Fossati, Marco;Falso, Silvia;Mantegazza, Renato;Battaglia, Alessandra;Fattorossi, Andrea;Evoli, Amelia
在这项研究中，我们采用了全面的免疫分析方法来确定接受利妥昔单抗治疗的重症肌无力患者对 SARS-CoV-2 感染和 mRNA 疫苗的先天和适应性免疫反应。在感染和 mRNA 疫苗接种后，通过多色细胞术对树突状细胞和自然杀伤细胞、B 细胞和 T 细胞亚群（包括用 SARS-CoV-2 肽刺激的产生 IFN-γ 的 T 细胞）进行分析。在相同条件下，测量血清中的抗刺突抗体和细胞因子的水平。尽管 B 细胞和体液反应受损，但利妥昔单抗患者在感染和疫苗接种后表现出完整的先天 CD8 T 细胞和 IFN-γ 特异性 CD4+ 和 CD8+ T 细胞反应，与对照组相当。没有观察到细胞因子介导的炎症级联的迹象。我们的研究提供了重症肌无力患者接受 B 细胞耗竭治疗后 SARS-CoV-2 感染和 mRNA 疫苗后保护性免疫反应的证据，并强调需要进行更大队列的前瞻性研究，以阐明 B 细胞在 SARS-CoV-2 免疫反应中的作用。
In this study we employed a comprehensive immune profiling approach to determine innate and adaptive immune response to SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis receiving rituximab. By multicolour cytometry, dendritic and natural killer cells, B- and T-cell subsets, including T-cells producing IFN-γ stimulated with SARS-CoV-2 peptides, were analysed after infection and mRNA vaccination. In the same conditions, anti-spike antibodies and cytokines’ levels were measured in sera. Despite the impaired B cell and humoral response, rituximab patients showed an intact innate, CD8 T-cell and IFN-γ specific CD4+ and CD8+ T-cell response after infection and vaccination, comparable to controls. No signs of cytokine mediated inflammatory cascade was observed. Our study provides evidence of protective immune response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis on B cell depleting therapy and highlights the need for prospective studies with larger cohorts to clarify the role of B cells in SARS-CoV-2 immune response.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
24.8
作者：
Kuri-Cervantes, Leticia;Pampena, Maria Betina;Betts, Michael R.
通讯作者：
Betts, Michael R.
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
肌无力重症患者的COVID-19疫苗接种：单中心病例系列。
影响因子：
7.8
作者：
Ruan Z;Tang Y;Li C;Sun C;Zhu Y;Li Z;Chang T
通讯作者：
Chang T
影响因子：
20.9
作者：
Frahm, Niklas;Fneish, Firas;Ellenberger, David;Haas, Judith;Loebermann, Micha;Parciak, Tina;Peters, Melanie;Poehlau, Dieter;Rodgers, Jeff;Roeper, Anna-Lena;Schilling, Sarah;Stahmann, Alexander;Temmes, Herbert;Zettl, Uwe K.;Middleton, Rodden M.
通讯作者：
Middleton, Rodden M.